Xenon Pharmaceuticals Inc.
XENEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Xenon Pharmaceuticals Inc. focuses on Biotechnology services and products. Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric. With a market capitalization of $3.42B, it sits in mid-cap territory. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Market Cap
$3.42B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
-7.48
EPS (TTM)
$-4.74
EPS (Fwd)
$-4.72
ROE
-43.6%
ROA
-28.0%
Cash
$930.7M
Total Debt
$6.4M
Free CF
-$203.5M
52W Change
-15.6%
Annual Financials
Cash vs Debt
Where XENE stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, XENE finished 39.35% below its 150-day moving average ($55.89) and 35.75% below its 200-day moving average ($52.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XENE overbought or oversold?
At the October 15, 2026 close, XENE's RSI(14) was 27.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $930.7M in cash and $6.4M in debt, XENE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$203.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -43.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $9.4M (2022) to $7.5M (2025), a 21% decline worth watching.
The relatively low beta of 0.60 suggests XENE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, XENE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing XENE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.